EpiVax Announces Licensing of COVID-19 Vaccine Candidate to EpiVax Therapeutics

PROVIDENCE,R.I.,Aug. 25,2020 --EpiVax,Inc. ("EpiVax"),a Rhode Island-based company and recognized leader in the field of computational vaccinology,today announced it has out-licensed its COVID-19 vaccine candidate,EPV-CoV-19,to EpiVax Therapeutics ("EVT"),a New York-based company previously named EpiVax Oncology.

Scientists at EpiVax designed EPV-CoV-19 – a peptide-based,epitope-driven vaccine – utilizing their validated computational toolkit (iVAX),which enabled the selection of sequences representing all circulating SARS-CoV-2 genomes that will drive a T cell-mediated immune response,with the goal of providing recipients with immune system "body armor",reducing their risk of severe COVID-19 disease.

With in-licensing the COVID-19 vaccine program,EVT is broadening its pipeline and application of its platform beyond its clinical-stage personalized cancer vaccine program. The venture-backed company will provide an ideal environment for funding and development of EPV-CoV-19. The company recently re-organized its executive team in preparation for the pipeline expansion and is raising $3M to support the new program.

Having received a positive pre-IND response from the FDA,EVT is progressing to a clinical trial. It has begun GMP peptide production and is preparing the IND submission in parallel.

Michael Princiotta,CSO at EVT,said,"EVT is pleased to welcome the COVID-19 vaccine program into our pipeline. We are eager to apply our vaccine platform and fundraising experience to advance EPV-CoV-19 into clinical trials."

Annie De Groot,CEO/CSO and cofounder of EpiVax,"The EpiVax team has done a fantastic job in the preclinical research phase. We are confident that EPV-CoV-19 will be safe and effective for frontline healthcare workers. We look forward to working with EVT to accelerate its progress to Phase I and beyond."

About EpiVax:

EpiVax has pioneered the use of in silico immunogenicity screening toolkits for therapeutics and vaccines. These toolkits,ISPRI and iVAX,are used for advancing product development at a global roster of companies. See the latest peer-reviewed publications athttps://www.frontiersin.org/articles/10.3389/fimmu.2020.00442/fulland https://www.frontiersin.org/articles/10.3389/fimmu.2020.01301/full formore information about recent applications of EpiVax's in silico vaccine design and protein therapeutic immunogenicity assessment tools.

About EVT:

EVT,founded in 2017,employs a world-leading technology,developed over 22 years by EpiVax,to design vaccines that aim to activate the body's T cells to cure or prevent disease in the host. EVT's pipeline includes a COVID-19 vaccine and a personalized bladder cancer vaccine.

Press Contact:

Annie De Groot,MD CEO/CSO,EpiVax

T: 401-272-2123

E: AnnieD@epivax.com

Logo - http://cusmail.com/res/2023/07-22/19/2f7f288e611d9a5fb69888292374d118.jpg